China bio firm dispels fears of serious blood clots from its COVID-19 vaccine

0 Comment(s)Print E-mail Xinhua, April 16, 2021
Adjust font size:

China's CanSino Biologics Inc (CanSinoBIO) has said that no serious blood clot cases were reported in the recipients of its COVID-19 vaccine Ad5-nCoV.

"No blood clot related serious adverse events have been reported in around one million vaccinations of Ad5-nCoV," CanSinoBIO said in a statement on Wednesday.

The statement came after U.S. federal health agencies on Tuesday called for a pause of the use of Johnson & Johnson's COVID-19 vaccine, which applies a similar technology to Ad5-nCoV, following some blood clots reports.

Although both vaccines developed by CanSinoBIO and Johnson & Johnson's contained another virus called adenovirus, CanSinoBIO's vaccine uses a different adenovirus from that for Johnson & Johnson's.

In mid-January, Russian pharma Petrovax said that 92.5 percent of Russian volunteers in trials of the Ad5-nCoV vaccine had shown high levels of antibodies, according to Russia's Interfax news agency.

So far, the Ad5-nCoV vaccine has been approved for emergency use in China, Hungary, Chile, Mexico and Pakistan.

Follow China.org.cn on Twitter and Facebook to join the conversation.
ChinaNews App Download
Print E-mail Bookmark and Share

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:    
    Racist, abusive and off-topic comments may be removed by the moderator.
Send your storiesGet more from China.org.cnMobileRSSNewsletter